Compare Adaptive Biotechnologies Corp (ADPT) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs VanEck Vietnam ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while VanEck Vietnam ETF trades at $18.22. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | VNM | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $19.80 |
52-Week Low | $10.24 | $14.51 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
VNM trades at $18.19, down 1.62% on the day, with technical indicators signaling a bearish trend. The stock faces selling pressure from moving averages and oscillators, while support and resistance cluster around $18. Recent news highlights underperformance relative to emerging markets and global equities, compounded by Vietnam-specific risks like power grid strain from heatwaves.
The outlook remains cautious due to weak technical momentum and external headwinds. Investment opportunities hinge on Vietnam's economic resilience and potential foreign inflows from FTSE Russell's reclassification. Key risks include geopolitical tensions, climate impacts on infrastructure, and sustained underperformance versus peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
